Ascletis logo

Ascletis

North America, North Carolina, United States, Chapel Hill

Description

Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.

Investor Profile

Ascletis has made 3 investments, with 0 in the past 12 months and 67% as lead.

Stage Focus

  • Series E (67%)
  • Series Unknown (33%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ascletis frequently co-invest with?

Altium Capital
North America, New York, United States, New York
Co-Investments: 1
Kleiner Perkins
North America, California, United States, Menlo Park
Co-Investments: 2
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 2
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1
Co-Investments: 1
PFM Health Sciences
North America, California, United States, San Francisco
Co-Investments: 1
Huimei Capital
Asia, Beijing, China, Beijing
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Ascletis?

Sagimet Biosciences

San Mateo, California, United States

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

BiopharmaBiotechnologyTherapeutics
Series UnknownFeb 11, 2021
Amount Raised: $80,000,000
Sagimet Biosciences

San Mateo, California, United States

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

BiopharmaBiotechnologyTherapeutics
Series EAug 5, 2019
Amount Raised: $7,000,000
Sagimet Biosciences

San Mateo, California, United States

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.

BiopharmaBiotechnologyTherapeutics
Series EFeb 13, 2019
Amount Raised: $18,000,000